Supplemental Financial Information (Unaudited)

12 Months Ended

Dec. 31, 2013

Supplemental Financial Information (Unaudited)[Abstract]

Supplemental Financial Information (Unaudited)

Note 10 - Supplemental Financial Information (Unaudited)

Quarterly financial information for the years ended December 31, 2013 and 2012 is presented in the following tables:

	Three months ended
	March 31,			June 30,			September 30,			December 31,
Fiscal year 2013
Revenue	$	6,475,138		$	4,295,400		$	3,488,142		$	3,653,927
Income (loss) from operations		(1,090,734	)		(1,481,729	)		(3,199,182	)		(5,067,563	)
Net income (loss)		(2,111,385	)		(1,236,372	)		(3,945,887	)		(4,424,709	)
Net income (loss) per share, basic		(0.04	)		(0.02	)		(0.08	)		(0.08	)
Net income (loss) per share, diluted		(0.04	)		(0.02	)		(0.08	)		(0.08	)
Fiscal year 2012
Revenue	$	6,149,052		$	6,316,998		$	6,696,126		$	6,013,711
Income (loss) from operations		(1,590,696	)		(1,458,204	)		(1,790,377	)		(1,427,113	)
Net income (loss)		(2,679,888	)		(756,543	)		(213,936	)		(1,269,748	)
Net income (loss) per share, basic		(0.06	)		(0.02	)		0.00			(0.03	)
Net income (loss) per share, diluted		(0.06	)		(0.02	)		0.00			(0.03	)

  Our net loss for 2013 includes approximately $3.3 million in merger and acquisition costs associated with the terminated merger with Theraclone, inclusive of a $1 million termination fee paid to Theraclone under the terms of the termination agreement entered into on December 1, 2013.